{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:41:21Z","timestamp":1760488881341,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T00:00:00Z","timestamp":1559952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T00:00:00Z","timestamp":1559952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s10637-019-00803-6","type":"journal-article","created":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T07:02:35Z","timestamp":1559977355000},"page":"584-598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-2381","authenticated-orcid":false,"given":"Jelena","family":"Dini\u0107","sequence":"first","affiliation":[]},{"given":"Carla","family":"R\u00edos-Luci","sequence":"additional","affiliation":[]},{"given":"Ieva","family":"Karpaviciene","sequence":"additional","affiliation":[]},{"given":"Inga","family":"Cikotiene","sequence":"additional","affiliation":[]},{"given":"Miguel X.","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Milica","family":"Pe\u0161i\u0107","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 M.","family":"Padr\u00f3n","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,6,8]]},"reference":[{"issue":"1","key":"803_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/1568011053352569","volume":"5","author":"J Zhou","year":"2005","unstructured":"Zhou J, Giannakakou P (2005) Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 5(1):65\u201371","journal-title":"Curr Med Chem Anticancer Agents"},{"issue":"4","key":"803_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253\u2013265. https:\/\/doi.org\/10.1038\/nrc1317","journal-title":"Nat Rev Cancer"},{"key":"803_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.cellbio.16.1.89","volume":"16","author":"KH Downing","year":"2000","unstructured":"Downing KH (2000) Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 16:89\u2013111. https:\/\/doi.org\/10.1146\/annurev.cellbio.16.1.89","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"1","key":"803_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2(1):48\u201358. https:\/\/doi.org\/10.1038\/nrc706","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"803_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0163-7258(85)90082-8","volume":"28","author":"JR Riordan","year":"1985","unstructured":"Riordan JR, Ling V (1985) Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther 28(1):51\u201375","journal-title":"Pharmacol Ther"},{"issue":"1","key":"803_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2217\/14622416.9.1.105","volume":"9","author":"FJ Sharom","year":"2008","unstructured":"Sharom FJ (2008) ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9(1):105\u2013127. https:\/\/doi.org\/10.2217\/14622416.9.1.105","journal-title":"Pharmacogenomics"},{"key":"803_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","volume":"39","author":"SV Ambudkar","year":"1999","unstructured":"Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361\u2013398. https:\/\/doi.org\/10.1146\/annurev.pharmtox.39.1.361","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"34","key":"803_CR8","doi-asserted-by":"publisher","first-page":"23875","DOI":"10.1074\/jbc.274.34.23875","volume":"274","author":"ML Gonzalez-Garay","year":"1999","unstructured":"Gonzalez-Garay ML, Chang L, Blade K, Menick DR, Cabral F (1999) A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem 274(34):23875\u201323882","journal-title":"J Biol Chem"},{"issue":"15","key":"803_CR9","first-page":"5803","volume":"61","author":"M Kavallaris","year":"2001","unstructured":"Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD, Haber M (2001) Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 61(15):5803\u20135809","journal-title":"Cancer Res"},{"issue":"6","key":"803_CR10","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1073\/pnas.040546297","volume":"97","author":"P Giannakakou","year":"2000","unstructured":"Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A 97(6):2904\u20132909. https:\/\/doi.org\/10.1073\/pnas.040546297","journal-title":"Proc Natl Acad Sci U S A"},{"key":"803_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fphar.2013.00089","volume":"4","author":"RN Ganapathi","year":"2013","unstructured":"Ganapathi RN, Ganapathi MK (2013) Mechanisms regulating resistance to inhibitors of topoisomerase II. Front Pharmacol 4:89. https:\/\/doi.org\/10.3389\/fphar.2013.00089","journal-title":"Front Pharmacol"},{"issue":"2","key":"803_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbcan.2007.10.004","volume":"1785","author":"BT McGrogan","year":"2008","unstructured":"McGrogan BT, Gilmartin B, Carney DN, McCann A (2008) Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785(2):96\u2013132. https:\/\/doi.org\/10.1016\/j.bbcan.2007.10.004","journal-title":"Biochim Biophys Acta"},{"issue":"20","key":"803_CR13","doi-asserted-by":"publisher","first-page":"11737","DOI":"10.1073\/pnas.191388598","volume":"98","author":"A Goncalves","year":"2001","unstructured":"Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, Wilson L, Jordan MA (2001) Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A 98(20):11737\u201311742. https:\/\/doi.org\/10.1073\/pnas.191388598","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"803_CR14","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1172\/JCI119642","volume":"100","author":"M Kavallaris","year":"1997","unstructured":"Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100(5):1282\u20131293. https:\/\/doi.org\/10.1172\/JCI119642","journal-title":"J Clin Invest"},{"key":"803_CR15","doi-asserted-by":"publisher","unstructured":"Podolski-Renic A, Bankovic J, Dinic J, Rios-Luci C, Fernandes MX, Ortega N, Kovacevic-Grujicic N, Martin VS, Padron JM, Pesic M (2017) DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells. European Journal of Pharmaceutical Sciences: Eur J Pharm Sci 105:159\u2013168. https:\/\/doi.org\/10.1016\/j.ejps.2017.05.011","DOI":"10.1016\/j.ejps.2017.05.011"},{"issue":"15","key":"803_CR16","first-page":"3663","volume":"59","author":"CC Zhang","year":"1999","unstructured":"Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ, Hait WN (1999) DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res 59(15):3663\u20133670","journal-title":"Cancer Res"},{"issue":"12","key":"803_CR17","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/sj.onc.1201658","volume":"16","author":"CC Zhang","year":"1998","unstructured":"Zhang CC, Yang JM, White E, Murphy M, Levine A, Hait WN (1998) The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 16(12):1617\u20131624. https:\/\/doi.org\/10.1038\/sj.onc.1201658","journal-title":"Oncogene"},{"key":"803_CR18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ejmech.2013.10.041","volume":"70","author":"I Karpaviciene","year":"2013","unstructured":"Karpaviciene I, Cikotiene I, Padron JM (2013) Synthesis and antiproliferative activity of alpha-branched alpha,beta-unsaturated ketones. Eur J Med Chem 70:568\u2013578. https:\/\/doi.org\/10.1016\/j.ejmech.2013.10.041","journal-title":"Eur J Med Chem"},{"issue":"5","key":"803_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.biopha.2011.04.015","volume":"65","author":"A Podolski-Renic","year":"2011","unstructured":"Podolski-Renic A, Andelkovic T, Bankovic J, Tanic N, Ruzdijic S, Pesic M (2011) The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines. Biomed Pharmacother 65(5):345\u2013353. https:\/\/doi.org\/10.1016\/j.biopha.2011.04.015","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"803_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nrd3373","volume":"10","author":"O Kepp","year":"2011","unstructured":"Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G (2011) Cell death assays for drug discovery. Nat Rev Drug Discov 10(3):221\u2013237. https:\/\/doi.org\/10.1038\/nrd3373","journal-title":"Nat Rev Drug Discov"},{"key":"803_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248\u2013254","journal-title":"Anal Biochem"},{"issue":"2","key":"803_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ccr.2008.07.002","volume":"14","author":"KE Gascoigne","year":"2008","unstructured":"Gascoigne KE, Taylor SS (2008) Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14(2):111\u2013122. https:\/\/doi.org\/10.1016\/j.ccr.2008.07.002","journal-title":"Cancer Cell"},{"issue":"5","key":"803_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.devcel.2004.09.002","volume":"7","author":"CL Rieder","year":"2004","unstructured":"Rieder CL, Maiato H (2004) Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 7(5):637\u2013651. https:\/\/doi.org\/10.1016\/j.devcel.2004.09.002","journal-title":"Dev Cell"},{"issue":"3","key":"803_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4161\/cc.10.3.14721","volume":"10","author":"H Nakano","year":"2011","unstructured":"Nakano H, Wang W, Hashizume C, Funasaka T, Sato H, Wong RW (2011) Unexpected role of nucleoporins in coordination of cell cycle progression. Cell Cycle 10(3):425\u2013433. https:\/\/doi.org\/10.4161\/cc.10.3.14721","journal-title":"Cell Cycle"},{"issue":"4","key":"803_CR25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ceb.2009.05.001","volume":"21","author":"J Fernandez-Martinez","year":"2009","unstructured":"Fernandez-Martinez J, Rout MP (2009) Nuclear pore complex biogenesis. Curr Opin Cell Biol 21(4):603\u2013612. https:\/\/doi.org\/10.1016\/j.ceb.2009.05.001","journal-title":"Curr Opin Cell Biol"},{"issue":"13","key":"803_CR26","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1073\/pnas.0306069101","volume":"101","author":"L Michel","year":"2004","unstructured":"Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty VV, Benezra R (2004) Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci U S A 101(13):4459\u20134464. https:\/\/doi.org\/10.1073\/pnas.0306069101","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"803_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.mrgentox.2007.10.020","volume":"651","author":"I Decordier","year":"2008","unstructured":"Decordier I, Cundari E, Kirsch-Volders M (2008) Mitotic checkpoints and the maintenance of the chromosome karyotype. Mutat Res 651(1\u20132):3\u201313. https:\/\/doi.org\/10.1016\/j.mrgentox.2007.10.020","journal-title":"Mutat Res"},{"issue":"1","key":"803_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ncb1208","volume":"7","author":"MA Lampson","year":"2005","unstructured":"Lampson MA, Kapoor TM (2005) The human mitotic checkpoint protein BubR1 regulates chromosome-spindle attachments. Nat Cell Biol 7(1):93\u201398. https:\/\/doi.org\/10.1038\/ncb1208","journal-title":"Nat Cell Biol"},{"issue":"5","key":"803_CR29","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1083\/jcb.200102093","volume":"154","author":"V Sudakin","year":"2001","unstructured":"Sudakin V, Chan GK, Yen TJ (2001) Checkpoint inhibition of the APC\/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J Cell Biol 154(5):925\u2013936. https:\/\/doi.org\/10.1083\/jcb.200102093","journal-title":"J Cell Biol"},{"issue":"9","key":"803_CR30","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2217\/fon.09.118","volume":"5","author":"WB Dalton","year":"2009","unstructured":"Dalton WB, Yang VW (2009) Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer. Future Oncol 5(9):1363\u20131370. https:\/\/doi.org\/10.2217\/fon.09.118","journal-title":"Future Oncol"},{"issue":"6","key":"803_CR31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1634\/theoncologist.5-6-510","volume":"5","author":"ED Israels","year":"2000","unstructured":"Israels ED, Israels LG (2000) The cell cycle. Oncologist 5(6):510\u2013513","journal-title":"Oncologist"},{"issue":"3","key":"803_CR32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.cell.2005.05.029","volume":"122","author":"SL Harvey","year":"2005","unstructured":"Harvey SL, Charlet A, Haas W, Gygi SP, Kellogg DR (2005) Cdk1-dependent regulation of the mitotic inhibitor Wee1. Cell 122(3):407\u2013420. https:\/\/doi.org\/10.1016\/j.cell.2005.05.029","journal-title":"Cell"},{"issue":"1","key":"803_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4161\/cc.6.1.3682","volume":"6","author":"MV Blagosklonny","year":"2007","unstructured":"Blagosklonny MV (2007) Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 6(1):70\u201374. https:\/\/doi.org\/10.4161\/cc.6.1.3682","journal-title":"Cell Cycle"},{"issue":"16","key":"803_CR34","doi-asserted-by":"publisher","first-page":"9357","DOI":"10.1074\/jbc.273.16.9357","volume":"273","author":"RU Janicke","year":"1998","unstructured":"Janicke RU, Sprengart ML, Wati MR, Porter AG (1998) Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273(16):9357\u20139360","journal-title":"J Biol Chem"},{"issue":"8","key":"803_CR35","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/sj.cdd.4401992","volume":"13","author":"LD Walensky","year":"2006","unstructured":"Walensky LD (2006) BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ 13(8):1339\u20131350. https:\/\/doi.org\/10.1038\/sj.cdd.4401992","journal-title":"Cell Death Differ"},{"issue":"3","key":"803_CR36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/med.20242","volume":"31","author":"RA Stanton","year":"2011","unstructured":"Stanton RA, Gernert KM, Nettles JH, Aneja R (2011) Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev 31(3):443\u2013481. https:\/\/doi.org\/10.1002\/med.20242","journal-title":"Med Res Rev"},{"issue":"Pt 3","key":"803_CR37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1242\/jcs.102.3.401","volume":"102","author":"MA Jordan","year":"1992","unstructured":"Jordan MA, Thrower D, Wilson L (1992) Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci 102(Pt 3):401\u2013416","journal-title":"J Cell Sci"},{"issue":"2","key":"803_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ddr.10023","volume":"55","author":"K Xu","year":"2002","unstructured":"Xu K, Schwarz PM, Ludue\u00f1a RF (2002) Interaction of nocodazole with tubulin isotypes. Drug Dev Res 55(2):91\u201396","journal-title":"Drug Dev Res"},{"issue":"2","key":"803_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P","volume":"27","author":"BM Ghadimi","year":"2000","unstructured":"Ghadimi BM, Sackett DL, Difilippantonio MJ, Schrock E, Neumann T, Jauho A, Auer G, Ried T (2000) Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosom Cancer 27(2):183\u2013190","journal-title":"Genes Chromosom Cancer"},{"issue":"1","key":"803_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0165-4608(00)00391-5","volume":"126","author":"T Tsushimi","year":"2001","unstructured":"Tsushimi T, Noshima S, Oga A, Esato K, Sasaki K (2001) DNA amplification and chromosomal translocations are accompanied by chromosomal instability: analysis of seven human colon cancer cell lines by comparative genomic hybridization and spectral karyotyping. Cancer Genet Cytogenet 126(1):34\u201338","journal-title":"Cancer Genet Cytogenet"},{"issue":"3","key":"803_CR41","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00280-013-2247-1","volume":"72","author":"A Podolski-Renic","year":"2013","unstructured":"Podolski-Renic A, Jadranin M, Stankovic T, Bankovic J, Stojkovic S, Chiourea M, Aljancic I, Vajs V, Tesevic V, Ruzdijic S, Gagos S, Tanic N, Pesic M (2013) Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing. Cancer Chemother Pharmacol 72(3):683\u2013697. https:\/\/doi.org\/10.1007\/s00280-013-2247-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"803_CR42","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1083\/jcb.148.5.863","volume":"148","author":"Y Chen","year":"2000","unstructured":"Chen Y, Simon SM (2000) In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity. J Cell Biol 148(5):863\u2013870","journal-title":"J Cell Biol"},{"issue":"1","key":"803_CR43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jare.2014.11.008","volume":"6","author":"HM Abdallah","year":"2015","unstructured":"Abdallah HM, Al-Abd AM, El-Dine RS, El-Halawany AM (2015) P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review. J Adv Res 6(1):45\u201362. https:\/\/doi.org\/10.1016\/j.jare.2014.11.008","journal-title":"J Adv Res"},{"issue":"7","key":"803_CR44","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/sj.bjc.6690507","volume":"80","author":"M Kavallaris","year":"1999","unstructured":"Kavallaris M, Burkhart CA, Horwitz SB (1999) Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 80(7):1020\u20131025. https:\/\/doi.org\/10.1038\/sj.bjc.6690507","journal-title":"Br J Cancer"},{"issue":"2","key":"803_CR45","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/sj.bjc.6605489","volume":"102","author":"C Stengel","year":"2010","unstructured":"Stengel C, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A (2010) Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer 102(2):316\u2013324. https:\/\/doi.org\/10.1038\/sj.bjc.6605489","journal-title":"Br J Cancer"},{"issue":"21","key":"803_CR46","doi-asserted-by":"publisher","first-page":"8881","DOI":"10.1158\/0008-5472.CAN-08-2037","volume":"68","author":"AL Risinger","year":"2008","unstructured":"Risinger AL, Jackson EM, Polin LA, Helms GL, LeBoeuf DA, Joe PA, Hopper-Borge E, Luduena RF, Kruh GD, Mooberry SL (2008) The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res 68(21):8881\u20138888. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2037","journal-title":"Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00803-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00803-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00803-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:34:52Z","timestamp":1678509292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00803-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,8]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00803-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2019,6,8]]},"assertion":[{"value":"17 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jelena Dini\u0107 declares that she has no conflict of interest. Carla R\u00edos-Luci declares that she has no conflict of interest. Ieva Karpaviciene declares that she has no conflict of interest. Inga Cikotiene declares that she has no conflict of interest. Miguel X. Fernandes declares that he has no conflict of interest. Milica Pe\u0161i\u0107 declares that she has no conflict of interest. Jos\u00e9 M. Padr\u00f3n declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}